NCT07298330Phase 3Active not recruiting

A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-08Estimated
Enrollment · participants80Estimated
Source updated2026-06-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source